BioMarin Pharmaceutical Inc. B1MR34.SA Stock
BioMarin Pharmaceutical Inc. Price Chart
BioMarin Pharmaceutical Inc. B1MR34.SA Financial and Trading Overview
BioMarin Pharmaceutical Inc. stock price | 235.55 BRL |
Previous Close | 215 BRL |
Open | 0 BRL |
Bid | 150 BRL x N/A |
Ask | 229.95 BRL x N/A |
Day's Range | 0 - 0 BRL |
52 Week Range | 0 - 295.34 BRL |
Volume | 0 BRL |
Avg. Volume | 23 BRL |
Market Cap | 83.42B BRL |
Beta (5Y Monthly) | 0.36647 |
PE Ratio (TTM) | 166.66667 |
EPS (TTM) | 2.21 BRL |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
B1MR34.SA Valuation Measures
Enterprise Value | 40.38B BRL |
Trailing P/E | 166.66667 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 37.333553 |
Price/Book (mrq) | 8.457907 |
Enterprise Value/Revenue | 18.071 |
Enterprise Value/EBITDA | 208.15 |
Trading Information
BioMarin Pharmaceutical Inc. Stock Price History
Beta (5Y Monthly) | 0.36647 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 295.34 BRL |
52 Week Low | 0 BRL |
50-Day Moving Average | 215.57 BRL |
200-Day Moving Average | 245.7 BRL |
B1MR34.SA Share Statistics
Avg. Volume (3 month) | 23 BRL |
Avg. Daily Volume (10-Days) | 0 BRL |
Shares Outstanding | 376.3M |
Float | 186.79M |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 0.0040% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | June 30, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 4.47% |
Operating Margin (ttm) | 4.15% |
Gross Margin | 47.28% |
EBITDA Margin | 8.68% |
Management Effectiveness
Return on Assets (ttm) | 0.91% |
Return on Equity (ttm) | 2.15% |
Income Statement
Revenue (ttm) | 2.23B BRL |
Revenue Per Share (ttm) | 11.98 BRL |
Quarterly Revenue Growth (yoy) | 11.50% |
Gross Profit (ttm) | 1.61B BRL |
EBITDA | 193.99M BRL |
Net Income Avi to Common (ttm) | 99.99M BRL |
Diluted EPS (ttm) | 1.29 |
Quarterly Earnings Growth (yoy) | 102.60% |
Balance Sheet
Total Cash (mrq) | 1.17B BRL |
Total Cash Per Share (mrq) | 6.22 BRL |
Total Debt (mrq) | 1.09B BRL |
Total Debt/Equity (mrq) | 22.86 BRL |
Current Ratio (mrq) | 4.94 |
Book Value Per Share (mrq) | 25.42 |
Cash Flow Statement
Operating Cash Flow (ttm) | 161.24M BRL |
Levered Free Cash Flow (ttm) | -2216500 BRL |
Profile of BioMarin Pharmaceutical Inc.
Country | Brazil |
State | CA |
City | San Rafael |
Address | 770 Lindaro Street |
ZIP | 94901 |
Phone | 415 506 6700 |
Website | https://www.biomarin.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 3082 |
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Q&A For BioMarin Pharmaceutical Inc. Stock
What is a current B1MR34.SA stock price?
BioMarin Pharmaceutical Inc. B1MR34.SA stock price today per share is 235.55 BRL.
How to purchase BioMarin Pharmaceutical Inc. stock?
You can buy B1MR34.SA shares on the São Paulo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioMarin Pharmaceutical Inc.?
The stock symbol or ticker of BioMarin Pharmaceutical Inc. is B1MR34.SA.
Which industry does the BioMarin Pharmaceutical Inc. company belong to?
The BioMarin Pharmaceutical Inc. industry is Biotechnology.
How many shares does BioMarin Pharmaceutical Inc. have in circulation?
The max supply of BioMarin Pharmaceutical Inc. shares is 379.55M.
What is BioMarin Pharmaceutical Inc. Price to Earnings Ratio (PE Ratio)?
BioMarin Pharmaceutical Inc. PE Ratio is 106.58371000 now.
What was BioMarin Pharmaceutical Inc. earnings per share over the trailing 12 months (TTM)?
BioMarin Pharmaceutical Inc. EPS is 2.21 BRL over the trailing 12 months.
Which sector does the BioMarin Pharmaceutical Inc. company belong to?
The BioMarin Pharmaceutical Inc. sector is Healthcare.